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Abstract
Introduction The clinical assessment of the myocardial
damage caused by anthracyclin (ANT)-therapy is diYcult.
Therefore a study was performed to evaluate non-invasive
markers of anthracyclin-induced cardiac eVects, with
emphasis on course-to-course variation.
Methods Eligible for study participation were patients,
without known cardiologic abnormalities who did not use
cardiotoxic medication (except for ANT-therapy), who had
previously completed at least three cycles of anthracyclin-
containing chemotherapy (n = 14) and patients who were
ANT-naïve and who were scheduled to receive doxorubi-
cin-containing chemotherapy (n = 12). Seven patients in
this last group also completed at least three cycles and were
available for follow-up assessments; thus a total population
of 21 patients (12F/9M) completed at least three courses
ANT-chemotherapy. In these patients blood samples and
ECG-recordings were taken within 6 months after comple-
tion of ANT-therapy. In 12 patients (10F/2M) assessments
were also done before, immediately afterwards and at 24 h
after each course of ANT.
Results and Conclusions In the patients who completed
chemotherapy, NT-proBNP was 277% (n = 21; 95% CI:
86–661%, P < 0.001) higher compared to healthy volun-
teers. During the Wrst course NT-proBNP rose 269%
(n = 12; 167–409%, P < 0.0001) at 24 h post-administra-
tion. The linear corrected QT (QTcL) directly after the Wrst
administration of ANT increased by 9.56 ms (n = 12; 3.85–
15.27, P < 0.001) and this prolongation was still present at
24 h, 11.48 ms (n = 12; 5.61–17.34, P < 0.0001). Both NT-
proBNP and QTcL returned to baseline before the start of
the next course and a similar pattern was observed during
each course. NT-proBNP and QTcL may be useful markers
for course-to-course evaluation of anthracyclin-induced
cardiotoxicity.
Keywords Anthracyclines · Cardiotoxicity · Biomarkers · 
Electrocardiography
Introduction
Anthracyclines, such as doxorubicin (DXR), cause serious
cardiac side-eVects (Singal et al. 1997). Acute tachy-
arrhythmias and acute heart failure may occur after high
doses, but these reactions are now rare due to changed dos-
age-schemes (e.g. slower infusion) with the aim to prevent
this. However, the sub-acute or chronic cardiac eVects of
anthracyclines remain a clinical problem. Clinically, anth-
racyclin-induced cardiotoxicity manifests itself as left ven-
tricular failure which develops insidiously over months to
years after completion of the anthracyclin-based chemo-
therapy and may result in congestive heart failure (CHF)
(Shan et al. 1996; Minotti et al. 2004).
Recent studies suggest an incidence of this type of car-
diotoxicity of 5% in doses up to 400 mg/m2 increasing to
48% in subjects receiving 700 mg/m2 (Swain et al. 2003).
But even at doses up to 150 mg/m2 CHF was occasionally
reported (Swain et al. 2003). In addition to the cumulative
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dose, age, gender and dosing schedule have been reported
as independent risk factors (Von HoV et al. 1979).
The mechanism of anthracyclin-induced cardiotoxicity
is not totally unravelled. It is likely that the decline in myo-
cardial function is related to apoptosis of cardiac myocytes
that occurs apparently at random in the myocardium (Thor-
burn and Frankel 2006). Anthracyclin-induced formation of
reactive oxygen species (ROS) in the presence of intracel-
lular iron, impaired homeostasis of intracellular iron and
calcium (that may facilitate the apoptosis induced by the
ROS) have been put forward as mechanisms. However,
other possible mechanisms have been suggested and it is
likely that anthracyclin-induced cardiotoxicity develops as
a result of a large number of diVerent insults (Minotti et al.
2004).
It is generally acknowledged that anthracyclin-induced
cardiotoxicity becomes evident after completion of the che-
motherapy. The gold standards to detect anthracyclin-
induced cardiotoxicity are cardiac imaging techniques or
myocardial biopsy. However, these methods have either the
disadvantage that cardiotoxicity is detected late, namely
when decline in left ventricular ejection fraction (LVEF)
already has occurred (imaging techniques) or that it is
highly invasive and based on the assumption that the dam-
age is equally distributed over the myocardium (biopsy).
Animal studies have shown that anthracyclin-induced
apoptosis can occur already after a single dose (Bennink
et al. 2004; Kumar et al. 2001; Arola et al. 2000). This is
line with the Wnding in humans that even at low cumulative
doses cardiotoxicity have been reported (Swain et al. 2003).
If this could be measured and conWrmed in humans, it
might be possible to detect anthracyclin-induced cardiotox-
icity in an early stage. Unfortunately, the assessment of
apoptosis itself in humans is diYcult, but it can be hypoth-
esised that the cell loss in the heart may be detected indi-
rectly. It is conceivable that cardiac damage results in
leakage of cardiac enzymes into the circulation, conduction
disturbances and that the loss of function will be compen-
sated by autocrine cardiac mechanisms. Indeed, it has been
reported that elevated concentrations of troponin, prolonga-
tion of QT-interval and increased levels of natriuretic pep-
tides are associated with anthracyclin-induced
cardiotoxicity after completion of chemotherapy (Meinardi
et al. 2001; Daugaard et al. 2005; Kilickap et al. 2005; Car-
dinale et al. 2004). However, little information is available
for the course-to-course eVects of anthracyclines on these
markers and thus they are not used to assess the early
eVects of anthracyclines on the heart. Additionally, the
evaluation of interventions or treatments designed to pre-
vent the damage requires a robust early and preferably
quantitative marker of the damage. Hence, there is a need
for biomarkers that can be used to detect early anthracyclin-
induced cardiotoxicity. Therefore a study was performed to
evaluate non-invasive markers of anthracyclin-induced car-
diotoxicity, with emphasis on course-to-course variation
during four subsequent chemotherapy courses.
Materials and methods
Study population
The study was carried out in 26 patients with various malig-
nancies who received DXR as chemotherapy, in combina-
tion with other chemotherapeutics (etoposide, vincristine,
ifosfamide, actinomycine, docetaxel, cyclophosphamide,
methotrexate, 5-Xurouracil, cisplatin) and a group of
healthy controls. One patient received epirubicin; for this
patient the epirubicin dose was converted to the equivalent
DXR-dose with the commonly used conversion factor of
0.5 (Launchbury and Habboubi 1993; Ewer and Benjamin
1996).
Eligible for study participation were patients who had
previously (within 6 months) completed at least three
cycles of anthracyclin-containing chemotherapy (n = 14)
and patients who were anthracyclin-naïve and who were
scheduled to receive DXR-containing chemotherapy
(n = 12). Seven patients in this last group also completed at
least three cycles and were available for follow-up assess-
ments; thus a total population of 21 patients completed at
least three courses ANT-chemotherapy. Of the anthracyl-
cin-naive group the majority (n = 9) received DXR com-
bined with cyclophosphamide for breast cancer. Two
patients were treated with DXR and cisplatin for a carci-
noma of the endometrium and osteosarcoma, respectively,
and one patient received DXR in combination with vincris-
tine, etoposide and ifosfamide for an Ewing sarcoma. The
median number of courses of this subpopulation was 4; four
patients received more courses, namely 5, 6 and 8 courses,
respectively.
Patients and volunteers with known cardiac abnormali-
ties, e.g. symptoms of angina pectoris, myocardial infarc-
tion or other myocardial abnormalities, or receiving other
drugs with a known or suspected cardiotoxic potential and
patients with clinically signiWcant abnormalities, other than
those related to their malignancy, were excluded form the
study. Subjects did not use any QT-prolonging agents,
except for 5-HT3-receptorantagonists for the prevention of
nausea. Especially patients with an impaired renal function,
haemoglobin level below 5 mmol/L or other clinically sig-
niWcant laboratory abnormalities other than those possibly
related to their disease were excluded. A summary of the
demographics of the patients and the volunteers is given in
Table 1.
The Medical Ethics Committee of Leiden University
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observational study. All patients were included after giving
written informed consent to participate.
Study outline
For each patient assessment consisted of blood sampling
and ECG-recording within 6 months after completion of the
chemotherapy. In the subpopulation of anthracyclin-naïve
patients (n = 12) measurements were made at each chemo-
therapy course. For comparability only data from the Wrst
four courses were used in the analysis. At each of these
assessments blood sampling and ECG recording were done
before (t = 0), at completion of the chemotherapy infusion
(t = 4) and at 24 h (t = 24) after the drug administration. For
the controls a single assessment was done.
Medication
All chemotherapy was prepared by the pharmacy of LUMC
according to the applicable guidelines. The median total
volume load for the anthracyclin-naïve subpopulation dur-
ing the courses was 250 mL over 2 h.
Sample handling and assays
Blood samples were centrifuged immediately after collec-
tion and serum/plasma was stored at ¡40° until analysis.
The samples were analysed for cardiac troponin T (cTnT),
the mass concentration of creatine kinase-MB (CK-MB
mass), atrial natriuretic peptide (ANP) and the N-terminal
propeptide of B-type natriuretic peptide (NT-proBNP).
Each individual assay was performed batchwise to avoid
interassay and interindividual variability using automated
and validated assays at the Central Laboratories for Clinical
Chemistry of LUMC. The concentrations of cTnT and NT-
proBNP in serum were determined using an automated
electrochemiluminescence immunometric assay on a Mod-
ular E170 Immunoanalyser (ECLIA, Roche Diagnostics,
Mannheim, Germany). Lower limits of detection and CV’s
were 0.01 ng/mL and 2.6–5.6% for cTnT and 5 ng/L and
2.3–3.2% for NT-proBNP. CK-MB (mass) was analysed in
serum using an automated analyser IMx with the kit pro-
vided by the manufacturer (Abbott Diagnostics, IL, USA;
detection limit 0.7 mg/L). Concentration of ANP was deter-
mined using an immunoextraction (RIA) with a C-terminal-
speciWc antiserum (Incstar, Stillwater, MN, USA; lower
limit of detection 0.1 pmol/L, CV: 6.8%–8.9%) as previ-
ously described (Wondergem et al. 2001). In addition hae-
moglobin, electrolytes and creatinine concentrations were
measured using routine methodology at the central labora-
tories for clinical chemistry of LUMC.
Renal function
Glomerular Wltration rate was estimated using the MDRD
formula: GFRestimate (mL/min) = 32,788 £ creatinine
(mol/L)¡1.154 £ age¡0.203 £ constant (1 for males, 0.742
for females) (Levey et al. 1999).
ECG recordings and analysis
For each patient a 5-min ECG recording was made using
the CardioPerfect device (Welch Allyn, Delft, The Nether-
lands). Heart rate (HR) and QT-interval were measured
using the software supplied with the device. Care was taken
to optimally assess the duration of the QT-interval as it has
been reported that in 10–15% of cases ECG’s Wducial
points (e.g. P-onset, QRS-onset and end of T-wave) are not
measured correctly by automated computer programs.
Therefore the ECG recordings were additionally analysed
after Wducial segment averaging (FSA) to obtain heart rate
and QT-interval. This analysis was done using Intraval
(Advanced Medical Systems, Maasdam, the Netherlands)
(Ritsema van Eck. 2002).
For both analyses correction of the QT-interval for heart
rate was done using Bazett’s formula (QTcB = QT/q(RR))
and using the linear correction method according to Fra-
mingham [QTcL = QT + 0.154 £ (1 ¡ RR)].
Table 1 Subject characteristics 
and cumulative doxorubicin 
dose
Patients Controls 
(n =1 4 )
Completed >3 course 
ANT-chemotherapy (n = 21)
ANT-naive 
(n =1 2 )
Age (years) 46 § 15 48 § 13 46 § 14
Gender (F/M) 12/9 10/2 8/6
BMI (kg/m2) 22.9 § 2.7 25.3 § 2.1 23.0 § 2.1
Cumulative doxorubicin dose (mg) 520 (270) 440 (138) NA
Estimated glomerular Wltration 
rate (mL/min)
84.5 § 26.4 86.2 § 21.2 NA
Haemoglobin (mol/L) 6.9 § 1.1 7.8 § 0.8 NA
BMI, age and the estimated glo-
merular Wltration rate (using the 
MDRD formula) are given as 
mean § SD. The cumulative 
dose is given as median with the 
interquartile range
ANT anthracyclin, BMI body 
mass index964 J Cancer Res Clin Oncol (2008) 134:961–968
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Statistics
Data from all patients were compared to the data obtained
in the group of controls. The analysis of variance was con-
ducted with factors group and gender and BMI and age as
covariate, contrasts between the two groups were calculated
along with 95% conWdence intervals and least square mean
estimates.
Data from the subpopulation of anthracyclin-naïve
patients were analysed for changes occurring during the
course (measurements at t = 0, 4 and 24) and whether there
was a diVerence between courses. Two analyses were per-
formed (Singal et al. 1997) analysis of variance with
(within subject) factors time (0, 4 and 24), course and time
by course using the data in original measurement units and
(Shan et al. 1996) analysis of variance on change from
baseline with baseline (t = 0) as covariate, with (within sub-
ject) factors time (4 and 24), course and time by course.
Least square means were calculated for the diVerent course/
time point combinations along with 95% conWdence inter-
vals.
In order to quantify the overall (average) time eVect, the
average change from baseline averaged over the four
courses for the t = 4 and 24 time point with 95% conWdence
interval was calculated within the ANOVA model.
All parameters, except for the ECG measurements, were
log transformed prior to analysis to realise a normal distri-
bution of the data and meet the requirements for ANOVA.
In case of log transformation results were back-transformed
resulting in geometric means and geometric mean ratios
(for the contrasts and change from baseline). Geometric
mean ratios were further translated into percentage change
along with their 95% conWdence intervals. Correlation anal-
ysis was performed on several biomarkers using regression
analysis. All calculations were performed using SAS
V9.1.2 (SAS Institute, Inc, Cary, NC, USA).
Results
Biochemical markers
Patients who completed chemotherapy had 277% (n =2 1 ;
95% CI: 86–661%, P < 0.001) higher NT-proBNP levels in
comparison to healthy volunteers (n =1 4 ) .
For the subpopulation of patients who were also fol-
lowed during chemotherapy it was Wrst investigated
whether diVerence in volume loading resulted in diVerent
NT-proBNP responses. As this was not the case the data are
given for the entire group. In these anthracyclin-naïve
patients, the estimated increase in NT-proBNP was 269%
(n = 12; 167–409%, P < 0.0001) at 24 h after the Wrst
DXR-course. Directly after completion of the DXR-infu-
sion no increment was observed (Fig. 1). Similar two to
threefold increases were found after the second, third and
fourth course of DXR-therapy. NT-proBNP levels had
returned to baseline before the start of each subsequent
DXR course. CK-MB and ANP showed no diVerences
between the groups, although there was a trend towards an
increased ANP in the group of patients who already com-
pleted chemotherapy (n = 21) (Table 2). Renal function
(estimated using the MDRD formula) was stable during the
four courses and none of the subjects experienced clinical
signiWcant electrolyte abnormalities during the courses.
Anthracyclin-naïve patients had higher ANP and NT-
proBNP than the healthy controls (n = 14) by 140.8%
(n = 12; 19.4–385.6%, P < 0.02), 113.1% (n = 12; 8.0–
320.1%, P < 0.04), respectively.
cTnT concentrations were below the limit of detection in
most cases and not further analysed for this reason.
In additional analyses the percentage change from base-
line was calculated for all courses together (Table 3). Rises
of 238% (n = 12; 149–358%, P < 0.0001), 44% (n =1 2 ;  4 –
101%, P <0 . 0 4 ) ,  2 6 %  ( n = 12; 4–52%, P < 0.02) for NT-
proBNP, ANP and CK-MB were found at 24 h.
There was no correlation between CK-MB on one hand
and ANP and NT-proBNP.
ECG
No diVerences in HR and (corrected) QT-time could be
observed when the patients who had completed the chemo-
therapy (n = 21) were compared with the healthy volunteers
(n =1 4 )  ( T a b l e2). However there was a trend to a slightly
prolonged QTc, corrected according to Bazett.
During each chemotherapy course (corrected) QT-time
was prolonged immediately after completion of a course
and remained so at 24 h after the DXR-course. As an exam-
Fig. 1 NT-proBNP, mean serum concentration (standard deviation) at
baseline, 4 and 24 h in 12 patients who were sampled during each
course of anthracyclin-containing chemotherapy
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ple: during the Wrst course QTc (using a linear correction
method) increased by 9.56 ms (n = 12; 3.85–15.27,
P · 0.001) at completion and was increased by 11.48 ms
(n = 12; 5.61–17.34, P · 0.0001) at 24 h. Similar prolonga-
tions were observed during the subsequent courses. Heart
rate did not change during the courses (Fig. 2). In the addi-
tional ECG-analyses using FSA, similar results were found.
Discussion
In the present study several markers that may be indicative
for cardiac damage after DXR administration were investi-
gated. The most important Wndings of this study are the
observed change in NT-proBNP and prolonged QTc-inter-
vals. This study indicates that at 24 h after each course of
anthracyclin chemotherapy as well as after completion of a
full chemotherapy regimen, signiWcant increases in serum
NT-proBNP are observed. Furthermore, the (corrected)
QT-interval was prolonged with each course (course-to-
course prolongation).
NT-proBNP is cleaved from proBNP when it is con-
verted into active BNP upon secretion. It is secreted equim-
olarly with BNP by the ventricle wall mainly in response to
wall stretch and its secretion may be enhanced by catechol-
amine’s, angiotensin II, endothelin and hypoxia (Hall
Table 2 (Bio)markers and the diVerences between patients receiving at least three courses of anthracyclin-containing chemotherapy and healthy
controls
Average values of biochemical markers and ECG parameters and contrasts between anthracyclin-chemotherapy completers and controls, including
95%-conWdence intervals and P values (for the biochemical markers contrasts are represented in percentage diVerence, for ECG parameters results
are shown in absolute diVerences)
ANP atrial natriuretic peptide, CK-MB creatine kinase isoenzyme MB, NT-proBNP N-terminal pro brain natriuretic peptide, HR heartrate, QT QT-
interval, QTc Bazett QT interval corrected according to Bazett, QTc linear QT interval corrected according to Framingham’s linear correction
method
Averages are estimated, as MIXED model analysis was used to correct for predose and missing values
Variable Controls 
(n = 14) 
Patients 
(n = 21) 
Patients versus 
controls
95%-ConWdence interval P value
Lower Upper
ANP (pmol/L) 11.3 20.7 82.9% ¡0.2% 235.0% 0.05
CK-MB mass (mg/L) 1.1 0.9 ¡15.7% ¡48.1% 37.0% 0.48
NT-proBNP (ng/L) 39.5 148.9 276.6% 86.3% 661.4% <0.001
HR (bpm) 67 71 4.20 ¡1.95 10.36 0.17
QT (ms) 400 400 ¡0.31 ¡18.1 17.47 0.97
QTc Bazett (ms) 420 433 13.05 ¡0.36 26.46 0.06
QTc linear (ms) 414 422 8.22 ¡2.68 19.13 0.13
Table 3 Summary table change from baseline (average of all four courses)
Average change (for all four courses) from baseline, 95%-conWdence intervals and P values (for the biochemical markers results represent per-
centage change, for ECG parameters results are shown in absolute changes)
ANP atrial natriuretic peptide, CK-MB creatine kinase isoenzyme MB, NT-proBNP N-terminal pro brain natriuretic peptide, HR heartrate, QT QT-
interval, QTc Bazett QT interval corrected according to Bazett, QTc linear QT interval corrected according to Framingham’s linear correction
method
Averages are estimated, as MIXED model analysis was used to correct for predose and missing values
4h 2 4h
Change 95%-ConWdence interval P value Change 95%-ConWdence interval P value
Lower Upper Lower Upper
ANP (pmol/L) 38.1% ¡0.3% 91.3% 0.05 44.3% 3.6% 101.2% 0.03
CK-MB mass (mg/L) ¡2.2% ¡18.6% 17.6% 0.80 26.1% 4.4% 52.2% 0.02
NT-proBNP (ng/L) 18.0% ¡14.6% 63.0% 0.30 237.9% 149.4% 357.8% <0.001
HR (bpm) ¡0.29  ¡3.37 2.79 0.85 1.46  ¡1.67 4.60 0.34
QT (ms) 10.95 3.91 17.98  0.004 10.96 3.77 18.15 0.005
QTc Bazett (ms) 10.79 4.70 16.88 0.002 15.82  9.66 21.97 <0.001
QTc linear (ms) 10.04 5.39 14.69 <0.001 13.13 8.40 17.85 <0.001966 J Cancer Res Clin Oncol (2008) 134:961–968
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2005). NT-proBNP is a well established marker for CHF
(Weber and Hamm 2006). Elevated levels of NT-proBNP
(and BNP) are most notably associated with CHF, but also
with other cardiac conditions (Silver et al. 2004). It is also
known that concomitant kidney failure results in more pro-
nounced elevations of NT-proBNP, especially in patients
with an ejection fraction below 35% (Luchner et al. 2005;
Masson et al. 2006). As all included patients had a stable
renal function during the study period, this could not
explain the elevations of NT-proBNP in our study.
Elevation of concentrations of natriuretic peptides asso-
ciated with previous exposure to anthracyclines has been
described before, but this is mostly reported after comple-
tion of chemotherapy (Meinardi et al. 2001; Daugaard et al.
2005; Suzuki et al. 1998). An important additional Wnding
of this study is that NT-proBNP is elevated relatively rap-
idly after exposure to anthracyclines. This eVect was pres-
ent for each individual subject, during each subsequent
chemotherapy cycle. Therefore, we assume that DXR
causes suYcient myocardial wall stress or neurohumoral
responses on catecholamines or angiotensin to result in
acutely elevated concentrations of NT-proBNP. This eVect
takes some time to develop as the NT-proBNP concentra-
tions were unchanged immediately after the courses
(t = 4 h). However, elevated concentrations were invariably
found in each patient at the 24 h time point. Although it
cannot totally be excluded that the increases in NT-proBNP
are (partly) caused by volume loading, this is highly
unlikely as the infused volumes were low.
Additionally, the increase in NT-proBNP was transient
as levels had returned to baseline at the subsequent course.
This temporal relationship suggests that the initial eVects of
DXR on the heart are at least partly reversible during its
Wrst phases or compensated for by other mechanisms. This
is plausible as animal studies indicated that the number of
apoptotic cardiomyocytes after DXR show a biphasic pat-
tern (Kumar et al. 2001). It is also in keeping with the
notion that in clinical practice overt anthracyclin-induced
cardiotoxicity develops after repeated exposure and failure
of compensatory mechanisms (Minotti et al. 2004).
When all courses were taken together, an increase in
ANP and CK-MB occurred after DXR. This eVect could
not be demonstrated for each individual patient-course
combination, most likely because the increase in ANP var-
Fig. 2 Heart rate (beats per minute) and QT-intervals (milliseconds) change from baseline with 95% CI error bars. a Heart rate, b QT-interval, c
QTc-interval (Bazett), d QTc-interval (linear)
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ied between individuals and the study population was
small. Furthermore cTnT level stayed below the detection
limit in most cases. Both cTnT and CK-MB are widely
used to assess myocardial injury in diVerent clinical condi-
tions (Malasky and Alpert 2002). There are conXicting data
in the literature with regard to cTnT (Kilickap et al. 2005;
Cardinale et al. 2004; Kismet et al. 2004; Fink et al. 1995;
Lipshultz et al. 1997). A possible explanation for this dis-
crepancy may be that many of the studies that failed to
show an eVect were small.
A surprising Wnding was that NT-proBNP and ANP
were higher in the group of patients prior to anthracyclin-
therapy when compared to healthy volunteers. Missov et al.
(1997) reported comparable results for cardiac Troponin I
in patients with hematologic malignancies prior to anthra-
cyclin-therapy. They suggested that patients with malignan-
cies could experience some myocardial wall stress because
of increased catecholamine release and an elevated sympa-
thetic drive associated with anaemia and reXex tachycardia.
However, our patients had normal haemoglobin concentra-
tions, were normotensive, and had a normal heart rate,
making this explanation for our population unlikely.
We also found signiWcant prolongations of the QT-inter-
val immediately after and at 24 h after each chemotherapy
cycle. As it has been shown that in 10–15% of cases ECG’s
Wducial points (e.g. P-onset, QRS-onset and end of T-wave)
are not measured correctly by automated computer pro-
grams, the analysis of QT-intervals was performed using
two methods which basically showed identical results (Rit-
sema van Eck 2002). The mechanism for the prolonged
repolarisation of the heart after DXR-administration is
unclear. Hypothetically, it may be a direct eVect of DXR on
cardiac repolarisation or the outcome of the loss of cardio-
myocytes. The Wrst explanation is supported by the obser-
vation that DXR is associated with acute arrhythmias and
sudden cardiac death; however, there are no reports of DXR
being a QT-prolonging drug. Although it is true that 5-HT3
receptor antagonists, which were used for the prevention of
nausea, can prolong the QT-interval. However, QT-prolon-
gations are present only very shortly after administration
(up to 20 min) and QT-intervals even decline thereafter
(Charbit et al. 2005). Therefore 5-HT3 receptor antagonists
cannot be responsible for the changes in QT-interval we
observed at 4 and 24 h after the chemotherapy. The second
explanation which links QT-interval prolongation to myo-
cardial cell death may be more plausible. Whatever the
cause of the QT-interval prolongation, it is certain that pro-
longed QT-intervals are linked to increased mortality and a
variety of cardiac disorders, including heart failure (Brook-
sby et al. 1999).
Although our exploratory study may have identiWed
promising markers to assess the course-to-course eVects of
DXR on the heart, it is important to also stress the limita-
tions of this study. Obviously, the Wndings reported here
should not be considered synonymous with anthracyclin-
induced cardiotoxicity, because no information is available
to relate our Wndings to a measure of left ventricular func-
tion. However, it is unlikely that during the observation
period of this study signs of ventricular dysfunction would
have been detected as it is known that for the majority of
the patients this develops over a longer period. Secondly,
the patients included in this study received diVerent dosing
regimens and cytostatic drug combinations, which may
have inXuenced the Wndings in this small cohort of patients.
At present there is no indication that this occurred, but our
group was probably too small to Wnd such diVerences
would they have been present.
In conclusion, the data indicate that NT-proBNP and the
QT-interval are sensitive markers for the early detection of
the course-to-course cardiac eVects of DXR. Further research
is needed to prospectively establish how the early changes in
these markers relate to left ventricular dysfunction.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pul-
kki LM (2000) Acute doxorubicin cardiotoxicity involves cardio-
myocyte apoptosis. Cancer Res 60:1789–1792
Bennink RJ, van den HoV MJ, van Hemert FJ, de Bruin KM, Spijkerb-
oer AL, Vanderheyden JL, Steinmetz N, Eck-Smit BL (2004) An-
nexin V imaging of acute doxorubicin cardiotoxicity (apoptosis)
in rats. J Nucl Med 45:842–848
Brooksby P, Batin PD, Nolan J, Lindsay SJ, Andrews R, Mullen M,
Baig W, Flapan AD, Prescott RJ, Neilson JM, Cowley AJ, Fox
KA (1999) The relationship between QT intervals and mortality
in ambulant patients with chronic heart failure. The United King-
dom heart failure evaluation and assessment of risk trial (UK-
HEART). Eur Heart J 20:1335–1341
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia
G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM
(2004) Prognostic value of troponin I in cardiac risk stratiWcation
of cancer patients undergoing high-dose chemotherapy. Circula-
tion 109:2749–2754
Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E,
Marty J (2005) Prolongation of QTc interval after postoperative
nausea and vomiting treatment by droperidol or ondansetron.
Anesthesiology 102:1094–1100
Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U,
Hesse B, Kjaer A (2005) Natriuretic peptides in the monitoring of
anthracycline induced reduction in left ventricular ejection frac-
tion. Eur J Heart Fail 7:87–93
Ewer MS, Benjamin RS (1996) Cardiotoxicity of chemotherapeutic
drugs. In: Perry MC (ed). Baltimore, pp 649–663
Fink FM, Genser N, Fink C, Falk M, Mair J, Maurer-Dengg K, Ham-
merer I, Puschendorf B (1995) Cardiac troponin T and creatine ki-
nase MB mass concentrations in children receiving anthracycline
chemotherapy. Med Pediatr Oncol 25:185–189968 J Cancer Res Clin Oncol (2008) 134:961–968
123
Hall C (2005) NT-ProBNP: the mechanism behind the marker. J Card
Fail 11:S81–S83
Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik
I, Kes S, Tekuzman G (2005) cTnT can be a useful marker for ear-
ly detection of anthracycline cardiotoxicity. Ann Oncol 16:798–
804
Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Buy-
ukpamukcu M (2004) Serum troponin T levels and echocardio-
graphic evaluation in children treated with doxorubicin. Pediatr
Blood Cancer 42:220–224
Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK (2001)
Apoptosis in adriamycin cardiomyopathy and its modulation by
probucol. Antioxid Redox Signal 3:135–145
Launchbury AP, Habboubi N (1993) Epirubicin and doxorubicin: a
comparison of their characteristics, therapeutic activity and toxic-
ity. Cancer Treat Rev 19:197–228
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A
more accurate method to estimate glomerular Wltration rate from
serum creatinine: a new prediction equation. ModiWcation of diet
in renal disease study group. Ann Intern Med 130:461–470
Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, Ott-
linger ME (1997) Predictive Value of Cardiac Troponin T in pedi-
atric patients at risk for myocardial injury. Circulation 96:2641–
2648
Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Hol-
mer S (2005) EVect of compensated renal dysfunction on ap-
proved heart failure markers: direct comparison of brain
natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension
46:118–123
Malasky BR, Alpert JS (2002) Diagnosis of myocardial injury by bio-
chemical markers: problems and promises. Cardiol Rev 10:306–317
Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov
ED, Clerico A, Tognoni G, Cohn JN (2006) Direct comparison of
B-type natriuretic peptide (BNP) and amino-terminal proBNP in
a large population of patients with chronic and symptomatic heart
failure: the Valsartan heart failure (Val-HeFT) data. Clin Chem
52:1528–1538
Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boom-
sma F, van den Berg MP, Volkers C, Haaksma J, de Vries EG,
Sleijfer DT, van der Graaf WT (2001) Prospective evaluation of
early cardiac damage induced by epirubicin-containing adjuvant
chemotherapy and locoregional radiotherapy in breast cancer pa-
tients. J Clin Oncol 19:2746–2753
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthra-
cyclines: molecular advances and pharmacologic developments
in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–
229
Missov E, Calzolari C, Davy JM, Leclercq F, Rossi M, Pau B (1997)
Cardiac troponin I in patients with hematologic malignancies. Co-
ron Artery Dis 8:537–541
Ritsema van Eck HJ (2002) Fiducial segment averaging to improve
cardiac time interval estimates. J Electrocardiol 35:89–93
Shan K, LincoV AM, Young JB (1996) Anthracycline-induced cardio-
toxicity. Ann Intern Med 125:47–58
Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr,
Francis GS, Mehra MR, Peacock WF, Fonarow G, Gibler WB,
Morrow DA, Hollander J (2004) BNP consensus panel 2004: a
clinical approach for the diagnostic, prognostic, screening, treat-
ment monitoring, and therapeutic roles of natriuretic peptides in
cardiovascular diseases. Congest Heart Fail 10:1–30
Singal PK, Iliskovic N, Li T, Kumar D (1997) Adriamycin cardiomy-
opathy: pathophysiology and prevention. FASEB J 11:931–936
Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I,
Kurabayashi M, Yamaoki K, Mitani K, Hirai H, Nagai R, Yazaki
Y (1998) Elevated B-type natriuretic peptide levels after anthra-
cycline administration. Am Heart J 136:362–363
Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in
patients treated with doxorubicin: a retrospective analysis of three
trials. Cancer 97:2869–2879
Thorburn A, Frankel AE (2006) Apoptosis and anthracycline cardio-
toxicity. Mol Cancer Ther 5:197–199
Von HoV DD, Layard MW, Basa P, Davis HL Jr, Von HoV AL, Ro-
zencweig M, Muggia FM (1979) Risk factors for doxorubicin-in-
duced congestive heart failure. Ann Intern Med 91:710–717
Weber M, Hamm C (2006) Role of B-type natriuretic peptide (BNP)
and NT-proBNP in clinical routine. Heart 92:843–849
Wondergem J, Strootman EG, Frolich M, Leer JW, Noordijk EM
(2001) Circulating atrial natriuretic peptide plasma levels as a
marker for cardiac damage after radiotherapy. Radiother Oncol
58:295–301